Seladelpar Reduces Liver Injury in Patients With PBC With and Without Cirrhosis
The phase 3 RESPONSE trial, presented at the AASLD Liver Meeting, showed that seladelpar, a novel selective peroxisome proliferator-activated receptor agonist, can reduce biomarkers...
Study Observes Delay From Lab Abnormalities to Diagnosis of PBC
A study presented at the AASLD Liver Meeting found that, on average, the time from symptom onset and/or laboratory abnormalities to primary biliary cholangitis...
Histological Stage Is Linked to Risk of Complications in Patients With PBC
A study presented at the AASLD Liver Meeting found that histological stage is associated with a risk of complications such as pruritus, esophageal varices,...
Moderate to Severe Pruritus Significantly Impacts Quality of Life in Patients With PBC
Pruritis is commonly associated with primary biliary cholangitis (PBC), and a study presented at the AASLD Liver Meeting indicated that this greatly impacts patients’...